Literature DB >> 29804077

Seronegative enteropathy and malnutrition: a diagnostic challenge.

James McCulloch1, Miriam Barclay2, Adam Levene3, Robert Fearn4.   

Abstract

A 21-year-old woman presented with a 2-week history of vomiting, diarrhoea and epigastric pain, with 9 kg weight loss over the last two months. Laboratory tests were normal with negative coeliac serology. Duodenal biopsies revealed total villous atrophy, crypt hypertrophy and intraepithelial lymphocytosis. A diagnosis of seronegative coeliac disease was made, and she started a gluten-free diet. However, she did not respond and her weight fell to 30.6 kg (body mass index 11), becoming dependent on parenteral nutrition. Her diagnosis was reconsidered and the histology reviewed. The histopathological features were of severe active chronic duodenitis. By diagnosis of exclusion, with the absence of other clear pathology, she was treated as Crohn's disease. She responded to third-line therapy with biologics. In this case, the patient had refractory villous atrophy and the mucosal features, in addition to response with anti-tumour necrosis factor therapy, suggest inflammatory bowel disease, although not with complete diagnostic certainty. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  crohn’s disease; gastrointestinal system; malabsorption; malnutrition; parenteral / enteral feeding

Mesh:

Substances:

Year:  2018        PMID: 29804077      PMCID: PMC5976131          DOI: 10.1136/bcr-2018-224397

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  6 in total

1.  Noncoeliac enteropathy: the differential diagnosis of villous atrophy in contemporary clinical practice.

Authors:  K Pallav; D A Leffler; S Tariq; T Kabbani; J Hansen; A Peer; A Bhansali; R Najarian; C P Kelly
Journal:  Aliment Pharmacol Ther       Date:  2011-12-06       Impact factor: 8.171

2.  Severe spruelike enteropathy associated with olmesartan.

Authors:  Alberto Rubio-Tapia; Margot L Herman; Jonas F Ludvigsson; Darlene G Kelly; Thomas F Mangan; Tsung-Teh Wu; Joseph A Murray
Journal:  Mayo Clin Proc       Date:  2012-06-22       Impact factor: 7.616

3.  HLA-DQ2.5 genes associated with celiac disease risk are preferentially expressed with respect to non-predisposing HLA genes: Implication for anti-gluten T cell response.

Authors:  Laura Pisapia; Alessandra Camarca; Stefania Picascia; Virginia Bassi; Pasquale Barba; Giovanna Del Pozzo; Carmen Gianfrani
Journal:  J Autoimmun       Date:  2016-04-12       Impact factor: 7.094

4.  The clinical and phenotypical assessment of seronegative villous atrophy; a prospective UK centre experience evaluating 200 adult cases over a 15-year period (2000-2015).

Authors:  Imran Aziz; Mohammad F Peerally; Jodie-Hannah Barnes; Vigneswaran Kandasamy; Jack C Whiteley; David Partridge; Patricia Vergani; Simon S Cross; Peter H Green; David S Sanders
Journal:  Gut       Date:  2016-09-07       Impact factor: 23.059

5.  Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study.

Authors:  Mickael Basson; Myriam Mezzarobba; Alain Weill; Philippe Ricordeau; Hubert Allemand; Francois Alla; Franck Carbonnel
Journal:  Gut       Date:  2015-08-06       Impact factor: 23.059

6.  Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma.

Authors:  Marisa DeGaetani; Christina A Tennyson; Benjamin Lebwohl; Suzanne K Lewis; Hussein Abu Daya; Carolina Arguelles-Grande; Govind Bhagat; Peter H R Green
Journal:  Am J Gastroenterol       Date:  2013-05       Impact factor: 10.864

  6 in total
  1 in total

1.  Nutritional Risk Index as a Prognostic Factor Predicts the Clinical Outcomes in Patients With Stage III Gastric Cancer.

Authors:  Haibin Song; Hongkai Sun; Laishou Yang; Hongyu Gao; Yongkang Cui; Chengping Yu; Haozhi Xu; Linqiang Li
Journal:  Front Oncol       Date:  2022-05-13       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.